Construction and Analysis of Early Prediction Model of Therapeutic Response of Patients with Psoriasis Treated with Scuchizumab
To investigate the influencing factors of the treatment reactivity of secuchiumab in patients with psoriasis and establish an early prediction model,from January 2020 to May 2022,192 patients with psoriasis in the authors'hospital were selected as the research objects,and all of them were treated with scuchizumab.After 12 weeks of treatment,the psoriasis area and severity index(PASI)scale was used to evaluate the response to treatment.PASI75 was the response to treatment and was divided into response group and non-response group.The relevant data of the two groups were observed,and the influencing factors of the treatment reactivity of secuchiumab were analyzed and screened by multi-factor Logistic regression model,and the prediction model was constructed by nomogram.The efficacy of the model was evaluated by correction curve.After 12 weeks of treatment,147 cases(76.56％)achieved PASI75 response and 45 cases(23.44％)failed to achieve PASI75 response and were classified as non-response group.The body mass index,the proportion of complications and the history of TNF inhibitor treatment in the response group were lower than those in the non-response group,and the course of the disease was shorter than those in the non-response group,with statistical significance(P＜0.05).Multivariate Logistic analysis shows:body mass index(OR=1.305,95％CI:1.063～1.601),duration of disease(OR=1.378,95％CI:1.148～1.655),comorbidities(OR=2.849,95％CI:1.079～7.523),history of TNF inhibitor treatment(OR=3.616,95％CI:1.040～12.573)were the risk factors for non-response to treatment(all P＜0.05).The C-index of treatment reac-tivity predicted by the above factors was 0.782(95％CI:0.701～0.863),and the correction curve showed that the predicted value of the model was basically consistent with the actual observation results.Body mass index,course of disease,treatment history of TNF inhibitors,and complications can predict the therapeutic response of patients with psoriasis in an early stage,and the early prediction model thus constructed has high application value.
PsoriasisScochizumabTherapeutic reactivityPrediction modelCourse of diseaseComplication
NETL
NSTL
万方数据
